A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6536
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood ; volume:6 ; number:1 ; day:21 ; month:7 ; year:2017 ; pages:15-24 ; date:7.2017
Neurology and Therapy ; 6, Heft 1 (21.7.2017), 15-24, 7.2017
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40120-017-0073-9
- URN
-
urn:nbn:de:1111-201708264241
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blennow, Kaj
- SpringerLink (Online service)
Ähnliche Objekte (12)
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease